For an early-stage digital health, MedTech, or biotech startup, entering the U.S. market is less a technology question than a strategy question. The evidence from consultants who work with ex-U.S. companies entering the American system points to one consistent conclusion: investors and partners respond to a coherent go-to-market plan — regulatory pathway, reimbursement rationale, and channel strategy — far more than to the underlying product. This guide lays out five interconnected factors that determine whether your U.S. entry is credible, and closes with a decision framework you can apply to your own plan.
Navigating the U.S. Health Tech Market: A Strategic Framework
The first factor is recognizing what kind of market you are entering. Blue Matter Consulting, a firm that builds U.S. go-to-market strategies for ex-US digital health companies, describes the American healthcare system as "fragmented (and highly complicated)," and reports rising demand from startups seeking help understanding its drivers and barriers. That fragmentation is not a footnote — it shapes every downstream decision about who buys, who reimburses, and who partners.
The backdrop is favorable but does not substitute for planning. An opinion article published through the U.S. National Library of Medicine notes that health technology startups have become a critical driver of innovation in healthcare delivery, with the COVID-19 pandemic accelerating the trend, and that understanding the sector's market size and growth informs investors, policymakers, and providers about opportunities and challenges. In other words, market growth attracts attention — but attention is not adoption, and adoption is what investors ultimately price.
Regulatory Pathway: Your Foundation for Market Entry
The second factor is a clearly framed regulatory pathway, because it is the foundation on which market access rests. Baker Tilly, a professional services firm whose life sciences specialists include former medical directors, CFOs, health economists, pharmaceutical executives, and epidemiologists, states that achieving market access for an innovative medical device, bio-pharmaceutical agent, or diagnostic test is critical to the sustainability of any life sciences company. Because market access activities touch every part of the product life cycle, the firm advises companies to evaluate their strategies early and identify opportunities to increase their chance of success.
For digital health specifically, Blue Matter's guidance adds a sequencing insight: for prescription digital therapeutics, it recommends gaining real-world experience before seeking FDA clearance, noting that most PDTs aim to be regulated, reimbursed, high-quality clinical interventions, but the U.S. market is still warming up to them. The implication for founders is that regulatory ambition should be calibrated to market readiness — a full-clearance pathway for a product category payers have not yet embraced can burn runway without producing revenue. Note that this is strategic commentary, not legal or regulatory advice; specific pathway decisions require qualified counsel.
Investor Appeal: Beyond Technology, Focus on Go-to-Market
The third factor is how you translate strategy into investor messaging. Blue Matter is direct on this point: navigating reimbursement options and explaining the rationale to investors is a critical first step to gaining confidence in the chosen go-to-market strategy. The firm's framing of its own client work — helping ex-U.S. startups understand the drivers and barriers of the U.S. system — reflects where investor skepticism concentrates: not on whether the technology works, but on whether the founders understand the market they are entering.
This is why go-to-market gaps, rather than technology gaps, tend to sink pitches. An investor evaluating a digital health company is effectively underwriting a commercialization plan: who pays, through what mechanism, and against which competitive alternatives. A startup that can articulate its regulatory posture, its reimbursement rationale, and its channel strategy is de-risking the investment in the terms investors actually use. The National Library of Medicine opinion piece reinforces the demand side — investors look to market size and growth trends to gauge opportunity — but growth alone does not answer the commercialization question. Your go-to-market narrative does.
Reimbursement Strategy: Unlocking Commercial Viability
The fourth factor is reimbursement, and it is where many otherwise strong plans stall. Blue Matter's analysis identifies a structural problem: there is no standardized reimbursement pathway for most digital health products in the U.S., and mechanisms such as CPT codes, NTAP, and DRG have varying applicability depending on the product. This article does not provide specific reimbursement codes — but the strategic point stands regardless of code: founders must be able to explain which mechanism their product could plausibly fit, and why.
That explanation is not a formality; it is a core test of U.S. market knowledge. Blue Matter ties reimbursement assessment directly to investor confidence, treating an evaluation of insurance reimbursement potential — and a pathway to achieve it — as central to demonstrating that a startup understands the market it is entering. Baker Tilly's checklist approach, built by specialists who have operated inside payer and provider organizations, makes the same point from the access side: securing reimbursement for devices and technologies requires deliberate, early planning across the product life cycle, not a post-launch scramble.
Partnership and Channel Strategy: Finding the Right Entry Point
The fifth factor is who will actually carry your product into the market. Blue Matter advises startups to spend time understanding the competitive landscape to identify where partnership opportunities exist — and, just as importantly, where a customer already has a "good enough" solution that will slow commercialization even against a "best solution." That distinction is a discipline: a superior product does not displace an adequate incumbent without a compelling reason to switch.
The firm also flags a shifting buyer landscape: big tech companies such as Amazon, retail pharmacies such as CVS, and employers such as Costco are developing more comprehensive solutions and may be interested in filling gaps in their service suites in novel ways. For a startup, that means partnership candidates are not limited to health systems — but each channel type brings different expectations about evidence, integration, and reimbursement, which loops back to factors two and four.
U.S. Health Tech Market Entry Decision Framework
Use the matrix below to align your decisions across the five factors. The analytical task is to connect your regulatory pathway choice to its downstream consequences for investor messaging, partnership options, and reimbursement viability — so that each strategic area reinforces the others rather than pulling in different directions.
| Strategic Area | Key Consideration | Investor / Partner Impact | Reimbursement Implications |
|---|---|---|---|
| Regulatory pathway | Calibrate clearance ambition to market readiness; for PDTs, Blue Matter recommends real-world experience before seeking FDA clearance | A clear, sequenced pathway de-risks the investment story and demonstrates U.S. market understanding | Regulated, reimbursed positioning is the goal for most PDTs, but the U.S. market is still warming to them |
| Reimbursement strategy | No standardized pathway exists for most digital health products; CPT, NTAP, and DRG have varying applicability | Per Blue Matter, explaining your reimbursement rationale to investors is a critical first step to GTM confidence | Assess insurance reimbursement potential early and define a plausible pathway to achieve it |
| Market access planning | Per Baker Tilly, market access affects every part of the product life cycle and is critical to company sustainability | Early, deliberate access planning signals operational maturity to investors and partners | Securing reimbursement for devices and technologies requires structured steps, not reactive fixes |
| Partnership / channel | Map the competitive landscape for "good enough" incumbents and partnership gaps | Big tech (Amazon), retail pharmacies (CVS), and employers (Costco) are emerging buyers and partners seeking to fill service gaps | Channel choice shapes which reimbursement mechanisms and evidence requirements apply |
| Investor positioning | Lead with go-to-market knowledge, not technology alone | Investor rejection typically traces to GTM gaps — regulatory, quality, or commercialization planning | A credible reimbursement narrative is the proof point of market knowledge investors look for |
The reasoning path is straightforward: your regulatory choice sets what you can claim and when; your reimbursement assessment determines whether the claim is commercially meaningful; your channel analysis determines who delivers it; and together they form the investor narrative. A lower-burden entry with early real-world evidence may suit a category the market is still warming to, while a full-clearance, reimbursement-led strategy demands a longer runway and a more developed payer case. Neither is universally right — the trade-off is between speed of entry and depth of defensibility, and your fundraising timeline should match the path you choose.
Charting Your Course: A Strategic Decision for U.S. Market Entry
Health tech founders should prioritize developing an integrated go-to-market strategy that clearly defines their regulatory pathway, articulates a viable reimbursement plan, and identifies strategic partners, as these factors are critical for attracting investors and achieving sustainable market access in the U.S. The evidence is consistent on this ordering: Baker Tilly frames market access as a life-cycle-long discipline critical to sustainability, and Blue Matter ties investor confidence directly to a well-explained reimbursement and go-to-market rationale.
The measurable indicator of success is successful fundraising rounds and established commercial partnerships for early-stage digital health startups. Those are the observable outcomes this framework is built to influence — and they are the milestones to track as you test your U.S. market fit. This guide covers the U.S. healthcare market only, is intended for early-stage startups rather than established enterprises, does not provide specific reimbursement codes, and does not guarantee any particular funding outcome.
